Séverine Guiu - Concepedia

Author

Séverine Guiu

Institut de Recherche en Cancérologie de Montpellier ORCID

Also Known As

A. Hardy-Bessard, Guiu, Séverine, P. J.Lamy, S Guiu, Séverine Guiu, S. Guiu, Severine Guiu, Séverine Guiu, Sévérine Guiu

171

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Institut de Recherche en Cancérologie de Montpellier Inserm Centre Georges François Leclerc Université de Montpellier Centre Oscar Lambret

About

Séverine Guiu is an author at Institut de Recherche en Cancérologie de Montpellier specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	20	1K
2	Health Sciences	7	7	438
3	Hepatology	2	2	90
4	Anatomy	1	1	63
5	Cell Biology	1	1	26

Séverine Guiu

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Céline Lefèbvre, Thomas Bachelot, Thomas Filleron, PLoS Medicine	2016	388
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer Boris Guiu, J. Petit, F. Bonnetain, Gut	2009	256
Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents Sylvain Ladoire, Franck Bonnetain, Mélanie Gauthier, The Oncologist Prognostic BiomarkersUrologyAngiogenesisAntiangiogenic AgentsGenitourinary Cancer	2011	170
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact Jean‐Marc Nabholtz, Catherine Abrial, Marie‐Ange Mouret‐Reynier, Annals of Oncology Breast OncologyMedicineTreatment ImpactImmunologyPathology	2014	122
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases William Jacot, Elvire Pons‐Tostivint, Jean‐Sébastien Frenel, Breast Cancer Research and Treatment Breast OncologyBrain MetastasesMedicinePathologyImmune Checkpoint Inhibitor	2016	117
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers William Jacot, Aurélie Maran-Gonzalez, Océane Massol, Cancers	2021	108
18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations Alexandre Cochet, Inna Dygai‐Cochet, Jean‐Marc Riedinger, European Journal of Nuclear Medicine and Molecular Imaging Positron Emission Tomography18F-fdg Pet/ctBreast OncologyMedical ImagingMedicine	2013	90
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Yahya Ashraf, Hanane Mansouri, Valérie Laurent‐Matha, Journal for ImmunoTherapy of Cancer	2019	90
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer William Jacot, Evelyne Lopez‐Crapez, Caroline Mollévi, Cancers	2020	88
HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy Olivier Humbert, Alexandre Cochet, Jean‐Marc Riedinger, European Journal of Nuclear Medicine and Molecular Imaging Breast OncologyMedicinePathologyEarly PredictionBreast Cancer	2014	80

Page 1